Samuel D Colella
CIK 1201580 · last filed 2021-11-19
Samuel D Colella is a corporate insider who has filed 110 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing shows the insider disposed of $12.7M of FLXN on Nov 19, 2021. Across all open-market trades the lifetime net is +$19.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $110.0M across reported positions. 30 SEC filings were submitted jointly with Brian G Atwood.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FLXN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 3630
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FLXN | Director | 0 | $24.07 | $0 | $25.22M | 21 | 2021-11-19 |
| STANDARD BIOTOOLS INC. (FLDM) Delisted | Director | 230,381 | $3.71 | $854.7K | -$2.05M | 35 | 2020-03-12 |
| GKOS | 10%+ Owner | 989 | $238.74 | $236.1K | -$816.7K | 2 | 2016-06-02 |
| INGN | 10%+ Owner | 15,180 | $6.12 | $92.8K | -$179.5K | 2 | 2015-05-11 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 41,742 | — | — | -$4.64M | 27 | 2014-10-03 |
| VCYT | Director | 3,594,989 | $25.92 | $93.18M | $0 | 1 | 2013-11-04 |
| Alexza Pharmaceuticals Inc. (ALXA) Delisted | Director | 4,730 | — | — | $0 | 8 | 2012-09-07 |
| JAZZ | Director | 44,024 | $243.54 | $10.72M | $0 | 10 | 2012-01-13 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | 10%+ Owner | 10,709,818 | — | — | $1.63M | 2 | 2009-09-21 |
| SYMYX TECHNOLOGIES INC (SMMX) Delisted | Director | 11,938 | — | — | $0 | 1 | 2007-06-14 |
| PODD | 38,301 | $149.81 | $5.74M | $0 | 1 | 2007-05-17 |
Recent Filings
110 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-11-19 | FLXN | Disp (D) | −1,496,564 | -$12.72M | EDGAR |
| 2021-06-28 | FLXN | Grant (A) | +4,500 | $0 | EDGAR |
| 2021-03-12 | FLXN | Other (J) | +2,198 | $0 | EDGAR |
| 2021-01-20 | FLXN | Other (J) | −2,509,615 | $0 | EDGAR |
| 2020-06-12 | FLXN | Grant (A) | +4,500 | $0 | EDGAR |
| 2020-03-12 | STANDARD BIOTOOLS INC. (FLDM) Delisted | Buy (P) | +20,000 | $54.3K | EDGAR |
| 2020-02-06 | STANDARD BIOTOOLS INC. (FLDM) Delisted | Grant (A) | +21,628 | $0 | EDGAR |
| 2019-08-28 | STANDARD BIOTOOLS INC. (FLDM) Delisted | Buy (P) | +2,000 | $10.4K | EDGAR |
| 2019-08-12 | STANDARD BIOTOOLS INC. (FLDM) Delisted | Buy (P) | +1,000 | $6.7K | EDGAR |
| 2019-08-09 | FLXN | Buy (P) | +2,000 | $21.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.